• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过血浆制品评估人类病毒性疾病的传播。

Evaluation of human viral disease transmission through plasma products.

作者信息

Heldebrant C M, Friedman A E, Fedor E J

出版信息

Dev Biol Stand. 1987;67:319-22.

PMID:2440744
Abstract

Alpha's Wet Heat-Treatment process is being applied to both Factor VIII (AHF) and Factor IX Complex (PTC). Twelve hemophilia A, five hemophilia B, and one von Willebrands patient have been followed for at least 6 months for evidence of non-A, non-B hepatitis. No ALT elevations were seen in the hemophilia B patients. There have been four cases of ALT elevation, three in hemophilia A patients and one in the von Willebrand's patient. A subset of these patients have been followed for over one year for anti-HTLV-III status. No patient, either hemophilia A, hemophilia B, or von Willebrand's seroconverted to anti-HTLV-III positive status. Intravenous gamma globulin was studied in 11 normal patients given a single infusion and in 23 immune deficient patients with multiple infusions and evaluations of liver enzymes over a two year period. No elevated ALT or AST values were seen in either group.

摘要

阿尔法湿热治疗法已应用于凝血因子VIII(抗血友病因子)和凝血因子IX复合物(凝血酶原复合物)。对12例甲型血友病患者、5例乙型血友病患者和1例血管性血友病患者进行了至少6个月的跟踪,以寻找非甲非乙型肝炎的证据。乙型血友病患者未出现谷丙转氨酶(ALT)升高。有4例ALT升高病例,其中3例为甲型血友病患者,1例为血管性血友病患者。对这些患者中的一部分进行了一年多的抗人类嗜T淋巴细胞病毒III型(HTLV-III)状态跟踪。无论是甲型血友病患者、乙型血友病患者还是血管性血友病患者,均未出现抗HTLV-III血清转化为阳性的情况。对11例接受单次输注的正常患者以及23例在两年期间接受多次输注并进行肝酶评估的免疫缺陷患者进行了静脉注射丙种球蛋白的研究。两组均未出现ALT或谷草转氨酶(AST)值升高的情况。

相似文献

1
Evaluation of human viral disease transmission through plasma products.通过血浆制品评估人类病毒性疾病的传播。
Dev Biol Stand. 1987;67:319-22.
2
Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.血友病和血管性血友病浓缩物治疗的发展与现状
Wien Klin Wochenschr. 1982 Oct 15;94(19):509-14.
3
Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.血友病和血管性血友病:2. 管理。加拿大血友病诊所主任协会
CMAJ. 1995 Jul 15;153(2):147-57.
4
Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada.血友病和血管性血友病:1. 诊断、综合护理与评估。加拿大血友病诊所主任协会。
CMAJ. 1995 Jul 1;153(1):19-25.
5
Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
Dev Biol Stand. 1987;67:303-10.
6
The incidence of HTLV-III/LAV seroconversion and non-A, non-B hepatitis in recipients of plasma products.
Dev Biol Stand. 1987;67:327-31.
7
Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.对血管性血友病中缺乏的、血小板聚集所必需的一种血浆因子进行定量测定。与凝血因子VIII促凝活性及抗原含量的关系。
J Clin Invest. 1973 Nov;52(11):2708-16. doi: 10.1172/JCI107465.
8
Progress and problems in hemophilia and von Willebrand's disease.血友病和血管性血友病的进展与问题
Adv Pediatr. 1984;31:137-77.
9
Hemophilia in Sweden. Studies on demography of hemophilia and surgery in hemophilia and von Willebrand's disease.瑞典的血友病。血友病及血友病和血管性血友病疾病的人口统计学与外科手术研究。
Acta Med Scand Suppl. 1984;684:1-72.
10
Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate.用巴氏消毒的凝血因子VIII浓缩物治疗甲型血友病或血管性血友病后,未出现抗1型和2型人类免疫缺陷病毒血清转化。
N Engl J Med. 1989 Oct 26;321(17):1148-52. doi: 10.1056/NEJM198910263211702.

引用本文的文献

1
The development of virus-free labile blood derivatives--a review.无病毒不稳定血液衍生物的发展——综述
Eur J Epidemiol. 1987 Jun;3(2):103-18. doi: 10.1007/BF00239746.